Cormorant Asset Management, LP Eye Point Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $1.74 Billion
- Q1 2024
A detailed history of Cormorant Asset Management, LP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 6,893,235 shares of EYPT stock, worth $60 Million. This represents 8.2% of its overall portfolio holdings.
Number of Shares
6,893,235
Previous 6,038,235
14.16%
Holding current value
$60 Million
Previous $140 Million
2.11%
% of portfolio
8.2%
Previous 8.4%
Shares
4 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$41.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$32.7 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$29.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$24.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.47MShares$21.5 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $296M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...